1. Academic Validation
  2. A novel danshensu/tetramethypyrazine derivative attenuates oxidative stress-induced autophagy injury via the AMPK-mTOR-Ulk1 signaling pathway in cardiomyocytes

A novel danshensu/tetramethypyrazine derivative attenuates oxidative stress-induced autophagy injury via the AMPK-mTOR-Ulk1 signaling pathway in cardiomyocytes

  • Exp Ther Med. 2021 Feb;21(2):118. doi: 10.3892/etm.2020.9550.
Caipeng Xie 1 Jingxiong Luo 1 Huihui Hu 1 Liang Wang 2 Pei Yu 1 Lipeng Xu 1 Yewei Sun 1 Yuqiang Wang 1 Luchen Shan 1
Affiliations

Affiliations

  • 1 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong 510000, P.R. China.
  • 2 Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, P.R. China.
Abstract

Myocardial ischemia/reperfusion injury (MIRI) is an inevitable and unsolved clinical problem in the treatment of ischemic heart diseases. Compound DT-010 is a novel danshensu/tetramethylpyrazine derivative and was examined as a candidate for treating MIRI. In the present study, MTT, Lactate Dehydrogenase assay and Hoechst staining data indicated that DT-010 attenuated tert-butylhydroperoxide (t-BHP)-induced oxidative damage by increasing cell survival, reducing cell damage and decreasing Apoptosis in H9c2 cardiomyocytes. Autophagy was assessed by western blotting for microtubule-associated protein 1A/1B-light chain 3 (LC3-II and LC3-I) expression, acridine orange and monodansylcadaverine staining for autophagosome formation and the monomeric red fluorescent protein-green fluorescent protein-LC3 assay for autophagic flow. t-BHP-induced cell damage was aggravated by the Autophagy agonist rapamycin and alleviated by the Autophagy blocker hydroxy-chloroquine, suggesting that Autophagy was involved in t-BHP-induced cardiomyocyte injury. DT-010 pretreatment significantly prevented t-BHP-induced cell damage, which was partially but significantly abolished by rapamycin and significantly improved by hydroxy-chloroquine treatment. DT-010 treatment inhibited t-BHP-induced Autophagy in H9c2 cells, reduced phosphorylation of 5'-AMP-activated protein kinase (AMPK) and promoted the phosphorylation of mTOR and unc-51 like Autophagy activating kinase 1 (ULK1). To conclude, DT-010 can serve as a potential candidate for myocardial ischemia-reperfusion injury therapy. The cardioprotective effects of DT-010 could be partially attributed to its inhibition of Autophagy via the AMPK-mTOR-Ulk1 signaling pathway.

Keywords

5'-AMP-activated protein kinase/mTOR/unc-51 like autophagy activating kinase 1 signaling pathway; autophagy; cardioprotection; danshensu/tetramethylpyrazine derivative; oxidative stress.

Figures